The colitis, leaky gut, and NSAID-damage literature is particularly well-developed
Oral GLP-1 medications are an exciting advance
2011;4(167):ra20
But important limitations exist: Most research is in animals, not humans Long-term safety beyond 12 weeks is uncharacterized Drug interactions haven't been formally studied Cancer relationship remains unclear Who should consider BPC-157: Those researching recovery support for injuries or gut issues Individuals willing to accept calculated risk with an experimental peptide People who can work with a knowledgeable healthcare provider Who should avoid it: Those with active cancer or high cancer risk Anyone on medications that might interact (especially cardiovascular, dopamine-affecting) Individuals unwilling to monitor their response carefully If you choose to use BPC-157, start conservatively (200 mcg daily), use proper injection technique, source from reputable suppliers, and track your body's response

Symptoms may include dizziness, blurred vision, anxiety, irritability, sweating, slurred speech, hunger, confusion, drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery